---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000159"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:56:46.351245+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%

## Summary
- Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.
- 680 mg SC batoclimab showed IgG reduction up to 87% (mean 81%) after 12 weeks; 340 mg produced lower IgG reductions.
- Dose response observed on anti-TSHR autoantibodies and clinical parameters including ATD dose reduction/discontinuation.
- Batoclimab generally well tolerated with no new safety signals.
- CEO says intent to focus future Graves' development on IMVT-1402, with plans announced later in 2024.

## SEC filing metadata
- accession: 0001764013-23-000159
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/0001764013-23-000159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000159/imvt-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000159
- JSON: https://secwatch.observer/filing/0001764013-23-000159.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.